Zacks Investment Research reiterated their sell rating on shares of Xencor (NASDAQ:XNCR) in a research report released on Saturday morning.
According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “
Several other analysts have also recently issued reports on XNCR. ValuEngine cut shares of Xencor from a hold rating to a sell rating in a research note on Monday, October 23rd. BidaskClub cut shares of Xencor from a sell rating to a strong sell rating in a research note on Friday, December 15th. Piper Jaffray Companies reaffirmed a buy rating and set a $35.00 price target on shares of Xencor in a research report on Sunday, November 12th. Cantor Fitzgerald initiated coverage on shares of Xencor in a research report on Wednesday, November 29th. They set an overweight rating and a $33.00 price target for the company. Finally, Canaccord Genuity set a $36.00 price target on shares of Xencor and gave the stock a buy rating in a research report on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Xencor has a consensus rating of Hold and a consensus target price of $30.80.
Shares of Xencor (XNCR) opened at $22.50 on Friday. Xencor has a 12 month low of $18.55 and a 12 month high of $28.64. The stock has a market cap of $1,060.00, a price-to-earnings ratio of -22.28 and a beta of 2.09.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative net margin of 148.29% and a negative return on equity of 15.26%. analysts anticipate that Xencor will post -1.1 EPS for the current year.
In other news, major shareholder John S. Stafford III acquired 24,653 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was bought at an average cost of $20.01 per share, with a total value of $493,306.53. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder John S. Stafford III acquired 50,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was purchased at an average cost of $19.58 per share, with a total value of $979,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 278,535 shares of company stock valued at $5,526,936. 4.14% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of XNCR. Great West Life Assurance Co. Can boosted its position in Xencor by 158.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 4,005 shares during the last quarter. SG Americas Securities LLC boosted its position in Xencor by 62.6% in the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,252 shares during the last quarter. Legal & General Group Plc boosted its position in Xencor by 4.5% in the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares during the last quarter. Principal Financial Group Inc. purchased a new position in Xencor in the 3rd quarter valued at about $201,000. Finally, Citadel Advisors LLC purchased a new position in Xencor in the 2nd quarter valued at about $224,000. 77.50% of the stock is owned by institutional investors.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.